Dermata Therapeutics (DRMA) Competitors $6.45 +0.22 (+3.50%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$6.54 +0.09 (+1.40%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. GELS, LPCN, LEXX, BLRX, ATNF, COCP, HOTH, MRKR, EDSA, and NEUPShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Gelteq (GELS), Lipocine (LPCN), Lexaria Bioscience (LEXX), BioLineRx (BLRX), 180 Life Sciences (ATNF), Cocrystal Pharma (COCP), Hoth Therapeutics (HOTH), MARKER THERAPEUTICS (MRKR), Edesa Biotech (EDSA), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Gelteq Lipocine Lexaria Bioscience BioLineRx 180 Life Sciences Cocrystal Pharma Hoth Therapeutics MARKER THERAPEUTICS Edesa Biotech Neuphoria Therapeutics Dermata Therapeutics (NASDAQ:DRMA) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do analysts prefer DRMA or GELS? Dermata Therapeutics presently has a consensus price target of $3.00, indicating a potential downside of 53.49%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to DRMA or GELS? In the previous week, Dermata Therapeutics had 3 more articles in the media than Gelteq. MarketBeat recorded 3 mentions for Dermata Therapeutics and 0 mentions for Gelteq. Dermata Therapeutics' average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score. Company Overall Sentiment Dermata Therapeutics Neutral Gelteq Neutral Which has higher valuation and earnings, DRMA or GELS? Gelteq has higher revenue and earnings than Dermata Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$12.29M-$16.41-0.39Gelteq$100K152.93-$2.33MN/AN/A Is DRMA or GELS more profitable? Gelteq's return on equity of 0.00% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -270.81% -179.96% Gelteq N/A N/A N/A Do insiders & institutionals believe in DRMA or GELS? 8.7% of Dermata Therapeutics shares are owned by institutional investors. 18.5% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryDermata Therapeutics beats Gelteq on 6 of the 10 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.97M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-0.3917.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book10.408.508.275.55Net Income-$12.29M-$55.06M$3.24B$259.03M7 Day Performance822.48%-3.98%-3.63%-4.56%1 Month Performance867.02%9.59%4.40%4.49%1 Year Performance100.31%6.72%25.97%18.05% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics0.4806 of 5 stars$6.45+3.5%$3.00-53.5%+160.1%$3.97MN/A-0.398Upcoming EarningsShort Interest ↑GELSGelteqN/A$1.90+3.7%N/AN/A$17.91MN/A0.00N/ALPCNLipocine2.5988 of 5 stars$3.31-2.6%$9.00+171.9%-38.0%$17.71M$11.20M-3.2510Positive NewsUpcoming EarningsLEXXLexaria Bioscience2.6891 of 5 stars$0.90+1.0%$4.00+342.5%-78.6%$17.68M$615.92K-1.357News CoverageAnalyst ForecastAnalyst RevisionGap DownBLRXBioLineRx2.0653 of 5 stars$4.08-1.9%$26.00+537.3%-86.1%$17.38M$28.94M-0.4640Gap DownATNF180 Life Sciences0.6042 of 5 stars$2.82-3.0%N/A+68.6%$17.18MN/A-0.197News CoverageAnalyst ForecastGap DownHigh Trading VolumeCOCPCocrystal Pharma2.7264 of 5 stars$1.68-2.9%$6.00+257.1%-4.6%$17.09MN/A-1.0710Positive NewsHOTHHoth Therapeutics2.8422 of 5 stars$1.26-4.2%$4.00+218.7%+89.1%$16.58MN/A-1.104News CoverageUpcoming EarningsAnalyst ForecastGap DownMRKRMARKER THERAPEUTICS4.1608 of 5 stars$1.43-7.7%$13.17+820.7%-72.1%$16.17M$6.59M-1.0860EDSAEdesa Biotech1.7211 of 5 stars$2.30-1.3%$5.00+117.4%-59.1%$16.15MN/A-1.4520Upcoming EarningsNEUPNeuphoria Therapeutics1.1655 of 5 stars$8.45-2.8%$21.00+148.5%N/A$15.89M$10K0.00N/A Related Companies and Tools Related Companies GELS Competitors LPCN Competitors LEXX Competitors BLRX Competitors ATNF Competitors COCP Competitors HOTH Competitors MRKR Competitors EDSA Competitors NEUP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRMA Stock Alerts